Supplied as a white to off-white crystalline powder, Flumethrin Pharma Grade API (model FLM-PH, CAS 69770-45-2) is a synthetic pyrethroid active substance intended for tablet, capsule, granule, oral suspension, and injectable suspension manufacture. The chemical identity is cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro-2-(4-chlorophenyl)ethenyl]-2,2-dimethylcyclopropanecarboxylate, molecular formula C₂₈H₂₂Cl₂FNO₃ and relative molecular mass 510.39 g/mol. The same crystalline substrate is released for direct compression, roller compaction, non-aqueous granulation, and oil-based injectable dispersion, but route-specific particle size, bioburden, and residual solvent attributes are assigned before release. Because no dedicated monograph for flumethrin exists in Ph.Eur. 11.0 or USP-NF 2024, the specification is assembled from ICH Q3A(R2), ICH Q3C(R8), ICH Q3D(R2), and VICH GL18, with in-house methods validated under ICH Q2(R1). Packaging is in double low-density polyethylene liners inside a fibre drum, with storage at 2–8 °C protected from light; the retest interval is 24 months in the unopened original package. Stereochemical composition is controlled during synthesis, because uncontrolled cis/trans ratios alter thermal behaviour, crystalline order, and the dissolution rate of the active.

What Limits Oral Granulation Throughput with Flumethrin?

Because flumethrin is practically insoluble in water, aqueous high-shear granulation frequently produces binder migration and broad granule size distributions rather than uniform drug layering. A low-dose tablet process at 2.5 wt% active loading in a 25 L vertical high-shear granulator using lactose monohydrate and microcrystalline cellulose typically requires 15–20 min dry premixing at impeller speed 120–180 rpm and chopper speed 800–1200 rpm before binder addition. When aqueous povidone K30 solution is introduced, overwetting creates a bimodal fraction above 850 µm, and content uniformity may fail the USP 905 acceptance value unless the granule porosity is controlled. For tablet strengths below 5 mg, direct compression or roller compaction is therefore preferred; if wet granulation cannot be avoided, an ethanolic granulation fluid reduces drug migration but mandates explosion-proof equipment and post-drying residual solvent verification under ICH Q3C(R8).

Fluid-bed granulation of oral granules can be performed by spraying an ethanolic flumethrin solution onto maize starch or lactose at inlet air temperature 35–45 °C and spray rate 5–15 g/min/kg carrier. Drying is continued to loss on drying 1.0–2.0%, with residual ethanol below 5000 ppm as a Class 3 solvent. Granule free-flowing character is assessed by Carr index and Hausner ratio; a target Carr index below 25% and Hausner ratio below 1.25 are typical for sachet or capsule filling. Published data for this exact flumethrin granulation configuration remain limited; process verification with batch-specific content uniformity and dissolution testing is required.

Capsule manufacture at unit strengths below 1 mg per hard capsule depends on ordered mixing rather than simple blending. At a 0.5 mg label strength and a 200 mg fill weight, the nominal active fraction is 0.25 wt%; colloidal silicon dioxide at 0.5–1.0 wt% and sodium stearyl fumarate at 1.0 wt% reduce segregation during encapsulation. Fill content uniformity is tested by USP 905, with an acceptance value below 15.0 for the initial stage. Because flumethrin is lipophilic, dissolution testing in 0.1 M HCl without surfactant under USP 711 apparatus 2 at 50 rpm may show low recovery; a medium containing 0.5% sodium dodecyl sulfate at 900 mL is typically used as a discriminatory but solubility-sufficient condition. The final release medium must be justified by biorelevant data; published flumethrin capsule dissolution results remain limited.

Specifications Governing Release of Flumethrin Pharma Grade API

The absence of an official monograph for flumethrin means the release specification is a hybrid of general pharmacopoeial methods and ICH thresholds. The HPLC assay uses a reversed-phase C18 column with UV detection at 230 nm, validated for specificity, linearity, accuracy, precision, and robustness under ICH Q2(R1). The limits in the table below are representative for FLM-PH when assigned to oral and injectable development; for a specific dossier, thresholds are adjusted to the maximum daily dose and route of administration.

For injectable development, the API is not a sterile product; terminal sterilisation or aseptic processing is performed after the suspension is compounded. The microbial limits above apply only to the non-sterile starting material.

In parenteral manufacturing, particle size distribution replaces chemical purity as the principal formulation variable. Flumethrin is practically insoluble across pH 4.0–8.0; injectable suspensions are therefore based on micronized active dispersed in medium-chain triglycerides or sesame oil, usually with sorbitan monooleate as a wetting agent. Jet milling with nitrogen at 6–8 bar produces a volume median diameter of 2–5 µm and D₉₀ of 10–15 µm by ISO 13320:2020. The milled powder is dispersed under high shear at 10,000–15,000 rpm for 15–30 min in a jacketed vessel maintained at 20–25 °C to avoid heat-induced isomer interconversion.

Subvisible particulate testing by light obscuration is performed according to USP 788 for particles ≥ 10 µm and ≥ 25 µm. Because the suspension is particulate and cannot be sterile-filtered, aseptic processing under ISO 14644-1 Class 5 conditions is the standard route. Viscosity of the final suspension is typically maintained below 1000 mPa·s to permit syringeability through a 21G needle; higher viscosity oily vehicles show reduced redispersibility after storage. Batch-to-batch variance in micronized particle size should be held within the D₉₀ range of 10–20 µm, because larger fractions may settle during holding periods and smaller fractions may increase surface area and chemical degradation rate.

If Terminal Moist-Heat Sterilisation Is Applied to Flumethrin Suspensions

If terminal moist-heat sterilisation is attempted at 121.1 °C for 15 min, the α-cyano ester group of flumethrin can undergo hydrolysis or cis/trans isomerisation, and the oily vehicle may develop acid value shifts. Preliminary thermal stress screening at 80 °C for 72 h in sealed ampoules has been used to rank vehicle and stabiliser choices, but published data for this specific flumethrin suspension configuration are limited. Where a sterile injectable is required, aseptic filtration of a solution is generally not applicable because of particle content. Therefore the suspension is compounded aseptically from sterile vehicle and pre-sterilised container components, with the API either sterilised by a validated dry-heat cycle or added through an aseptic transfer line. If terminal sterilisation is unavoidable, it is qualified only after characterisation of degradation products and subvisible particulate aggregation.

Technical-Grade Flumethrin versus Pharma-Grade and Alternative Pyrethroids

Compared with technical-grade flumethrin, FLM-PH differs in assay, related substances, residual solvent control, elemental impurity certification, and particle size. Technical-grade material from veterinary topical raw streams may contain 85–95% flumethrin with variable cis/trans ratios and unknown late-eluting impurities; it is normally not tested against ICH Q3D(R2) parenteral elemental limits or ICH Q3C(R8) Class 2 residual solvent limits. FLM-PH is released at not less than 98.0% assay and is controlled for individual unspecified impurities at or below 0.10%. When compared with deltamethrin, cypermethrin, and permethrin, flumethrin possesses a 4-fluorophenoxy moiety and two chlorine substituents that raise lipophilicity; reported log P values exceed 5.0. This property reduces aqueous dissolution and shifts formulation toward non-aqueous granulation, oil-based injectables, and surfactant-rich dissolution media. The stereochemical instability of the α-cyano ester is the main quality risk, not assay loss alone.

Batch-to-batch control of the crystallisation and milling steps is essential because changes in crystal habit alter flowability, particle surface area, and suspension sedimentation. The milled active may exhibit increased electrostatic adhesion at relative humidity above 60%, requiring handling under controlled humidity or nitrogen. Flumethrin should not be blended with strongly alkaline excipients because the ester undergoes hydrolysis above pH 8.0; contact with oxidising agents accelerates degradation of the cyclopropane ring.